The current era of metabolic medicine is defined by GLP-1. From Ozempic to Zepbound, the glucagon-like peptide-1 receptor agonist has become the gold standard for weight loss, fundamentally altering the pharmaceutical landscape. However, a new hypothesis from the very scientists who helped pioneer these treatments suggests we may be able to achieve similar results by bypassing this specific hormone altogether.
Researchers Richard DiMarchi and Matthias Tschöp are testing an experimental molecule that targets two other hormones: GIP (glucose-dependent insulinotropic polypeptide) and glucagon. Crucially, their approach sidesteps GLP-1 entirely. In studies involving rodents and monkeys, high doses of this compound produced weight loss comparable to existing therapies, challenging the assumption that GLP-1 is the essential, indispensable ingredient in the modern weight-loss toolkit.
This shift is more than a matter of biochemical curiosity; it is a quest for better tolerability. While effective, current GLP-1 drugs are frequently associated with gastrointestinal side effects that lead many patients to discontinue treatment. By activating different hormonal pathways, researchers hope to create a more refined intervention—one that maintains the efficacy of current blockbusters while easing the physiological burden on the patient.
As the pharmaceutical industry races to diversify its portfolio of obesity treatments, the work of DiMarchi and Tschöp serves as a reminder that the first breakthrough is rarely the final word. The next generation of metabolic drugs may look less like a refinement of the status quo and more like a fundamental pivot in how we understand the body’s regulatory systems.
With reporting from STAT News.
Source · STAT News (Biotech)
